Tela Bio Inc (TELA)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$0.78-6.90%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · TELA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -86.6% |
| Our one-year growth estimate | diamond | 6.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 93.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 43 industry peers
TELA — credit agreement
Dated 2026-09-29
Entry into a Material Definitive Agreement. On September 28, 2026, TELA Bio, Inc. (the “ Company ”) entered into a Limited Consent to Credit Agreement and Guaranty (the “ Limited Consent ”) with Perceptive Credit Holdings V, LP, as administrative agent and collateral agent (the “ Administrative Agent ”), and the lenders party thereto constituting the Required Lenders under the Credit Agreement (as defined below) (the “ Consenting Lenders ”). As previously disclosed on November 14, 2025, the C…
Why it matters: TELA plans to cut annual costs by $17 million and extend its cash runway into 2028. The savings need to show up in reported costs.
Supportive ifOn the November 12 call, management reports lower costs. The $17 million annual savings plan remains on track.
Worry ifManagement reports little or no drop in costs, or cuts the planned annual savings below $17 million.
Why it matters: Lower OviTex PRS volumes drove much of Q2's revenue decline. A rebound would help test management's plan to improve sales.
Supportive ifOn the November 12 call, management says OviTex PRS units were flat or higher year over year in Q3.
Worry ifManagement reports that OviTex PRS units fell further year over year in Q3.
Why it matters: Management said it aims to return to growth in the second half. Q2 revenue fell 4% year over year.
Supportive ifOn the November 12 earnings call, Q3 revenue is above $19.3 million, its Q2 2026 level, and above Q3 2025 revenue.
Worry ifQ3 revenue is below Q3 2025, with OviTex PRS volumes or price and mix still weighing on sales.
Why it matters: A September notice raised a risk to TELA's Nasdaq listing. A clear compliance update would resolve that near-term issue.
Watch forTELA says Nasdaq confirmed it meets the rules to stay listed.
Also watch forNasdaq sets a delisting date or TELA reports it failed to meet the listing rules.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$392 on $10,000 · ±3.9% | How much price usually moves either way. |
| Bad day | $896 loss on $10,000 · 9.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,331 loss on $10,000 · 53.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: FDA clearance lets TELA add Liora to its product range. Sales would show whether surgeons take up the new product.
Supportive ifManagement gives a U.S. launch update and reports Liora orders or sales on the November 12 call.
Worry ifManagement reports a launch delay, supply issue, or no Liora orders or sales in its update.